Cargando…
NF1 mutations in conjunctival melanoma
BACKGROUND: Conjunctival melanoma is a potentially deadly eye tumour. Despite effective local therapies, tumour recurrence and metastasis remain frequent. The genetics of conjunctival melanomas remain incompletely understood. METHODS: A large cohort of 63 conjunctival melanomas was screened for gene...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943412/ https://www.ncbi.nlm.nih.gov/pubmed/29559732 http://dx.doi.org/10.1038/s41416-018-0046-5 |
_version_ | 1783321620174077952 |
---|---|
author | Scholz, S. L. Cosgarea, I. Süßkind, D. Murali, R. Möller, I. Reis, H. Leonardelli, S. Schilling, B. Schimming, T. Hadaschik, E. Franklin, C. Paschen, A. Sucker, A. Steuhl, K. P. Schadendorf, D. Westekemper, H. Griewank, K. G. |
author_facet | Scholz, S. L. Cosgarea, I. Süßkind, D. Murali, R. Möller, I. Reis, H. Leonardelli, S. Schilling, B. Schimming, T. Hadaschik, E. Franklin, C. Paschen, A. Sucker, A. Steuhl, K. P. Schadendorf, D. Westekemper, H. Griewank, K. G. |
author_sort | Scholz, S. L. |
collection | PubMed |
description | BACKGROUND: Conjunctival melanoma is a potentially deadly eye tumour. Despite effective local therapies, tumour recurrence and metastasis remain frequent. The genetics of conjunctival melanomas remain incompletely understood. METHODS: A large cohort of 63 conjunctival melanomas was screened for gene mutations known to be important in other melanoma subtypes by targeted next-generation sequencing. Mutation status was correlated with patient prognosis. RESULTS: Frequent mutations in genes activating the MAP kinase pathway were identified. NF1 mutations were most frequent (n = 21, 33%). Recurrent activating mutations were also identified in BRAF (n = 16, 25%) and RAS genes (n = 12, 19%; 11 NRAS and 1 KRAS). CONCLUSIONS: Similar to cutaneous melanomas, conjunctival melanomas can be grouped genetically into four groups: BRAF-mutated, RAS-mutated, NF1-mutated and triple wild-type melanomas. This genetic classification may be useful for assessment of therapeutic options for patients with metastatic conjunctival melanoma |
format | Online Article Text |
id | pubmed-5943412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-59434122019-04-15 NF1 mutations in conjunctival melanoma Scholz, S. L. Cosgarea, I. Süßkind, D. Murali, R. Möller, I. Reis, H. Leonardelli, S. Schilling, B. Schimming, T. Hadaschik, E. Franklin, C. Paschen, A. Sucker, A. Steuhl, K. P. Schadendorf, D. Westekemper, H. Griewank, K. G. Br J Cancer Article BACKGROUND: Conjunctival melanoma is a potentially deadly eye tumour. Despite effective local therapies, tumour recurrence and metastasis remain frequent. The genetics of conjunctival melanomas remain incompletely understood. METHODS: A large cohort of 63 conjunctival melanomas was screened for gene mutations known to be important in other melanoma subtypes by targeted next-generation sequencing. Mutation status was correlated with patient prognosis. RESULTS: Frequent mutations in genes activating the MAP kinase pathway were identified. NF1 mutations were most frequent (n = 21, 33%). Recurrent activating mutations were also identified in BRAF (n = 16, 25%) and RAS genes (n = 12, 19%; 11 NRAS and 1 KRAS). CONCLUSIONS: Similar to cutaneous melanomas, conjunctival melanomas can be grouped genetically into four groups: BRAF-mutated, RAS-mutated, NF1-mutated and triple wild-type melanomas. This genetic classification may be useful for assessment of therapeutic options for patients with metastatic conjunctival melanoma Nature Publishing Group UK 2018-03-21 2018-05-01 /pmc/articles/PMC5943412/ /pubmed/29559732 http://dx.doi.org/10.1038/s41416-018-0046-5 Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International licence (CC BY 4.0). |
spellingShingle | Article Scholz, S. L. Cosgarea, I. Süßkind, D. Murali, R. Möller, I. Reis, H. Leonardelli, S. Schilling, B. Schimming, T. Hadaschik, E. Franklin, C. Paschen, A. Sucker, A. Steuhl, K. P. Schadendorf, D. Westekemper, H. Griewank, K. G. NF1 mutations in conjunctival melanoma |
title | NF1 mutations in conjunctival melanoma |
title_full | NF1 mutations in conjunctival melanoma |
title_fullStr | NF1 mutations in conjunctival melanoma |
title_full_unstemmed | NF1 mutations in conjunctival melanoma |
title_short | NF1 mutations in conjunctival melanoma |
title_sort | nf1 mutations in conjunctival melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943412/ https://www.ncbi.nlm.nih.gov/pubmed/29559732 http://dx.doi.org/10.1038/s41416-018-0046-5 |
work_keys_str_mv | AT scholzsl nf1mutationsinconjunctivalmelanoma AT cosgareai nf1mutationsinconjunctivalmelanoma AT sußkindd nf1mutationsinconjunctivalmelanoma AT muralir nf1mutationsinconjunctivalmelanoma AT molleri nf1mutationsinconjunctivalmelanoma AT reish nf1mutationsinconjunctivalmelanoma AT leonardellis nf1mutationsinconjunctivalmelanoma AT schillingb nf1mutationsinconjunctivalmelanoma AT schimmingt nf1mutationsinconjunctivalmelanoma AT hadaschike nf1mutationsinconjunctivalmelanoma AT franklinc nf1mutationsinconjunctivalmelanoma AT paschena nf1mutationsinconjunctivalmelanoma AT suckera nf1mutationsinconjunctivalmelanoma AT steuhlkp nf1mutationsinconjunctivalmelanoma AT schadendorfd nf1mutationsinconjunctivalmelanoma AT westekemperh nf1mutationsinconjunctivalmelanoma AT griewankkg nf1mutationsinconjunctivalmelanoma |